Economic Evaluation of Nevirapine plus Raltegravir as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1 Infected Patients

Valutazione economica della combinazione nevirapina/raltegravir quale terapia antiretrovirale di mantenimento nei pazienti con infezione da HIV-1 in soppressione virologica

Authors

  • Roberto Ravasio Health Publishing & Services, Milano - Italy
  • Fabio Rigo Unità Operativa di Malattie Infettive, Ospedale “G.B. Rossi”, Verona - Italy
  • Emanuela Lattuada Unità Operativa di Malattie Infettive, Ospedale “G.B. Rossi”, Verona - Italy
  • Ercole Concia Unità Operativa di Malattie Infettive, Ospedale “G.B. Rossi”, Verona - Italy
  • Massimiliano Lanzafame Unità Operativa di Malattie Infettive, Ospedale “G.B. Rossi”, Verona - Italy

DOI:

https://doi.org/10.33393/grhta.2016.416

Keywords:

Antiretroviral therapy, Cost, Nevirapine, Raltegravir

Abstract

Background A one-year cost analysis was conducted to estimate the impact on the Italian National Health Service (NHS) of nevirapine plus raltegravir administration as maintenance antiretroviral therapy in virologically suppressed HIV-1 infected patients. Methods Patient data were retrieved from the electronic medical record system in use (year 2014) in a reference HIV centre in Northern Italy. The analysis considered patients with long-term (more than one year) virological suppression (HIV-1 RNA <50 copies/ml) on Highly Active Antiretroviral Therapy (HAART) and no prior exposure to integrase inhibitors (INIs). To estimate the total HAART expenditure, we calculated the annual treatment cost for each enrolled patients. Subsequently, to estimate the dual therapy hypothetical expenditure, we assumed to treat the same patients with nevirapine (400 mg) and raltegravir (400 mg twice daily). We took into account only drug costs (ex-factory prices, included all discounts and VAT) from the perspective of the Italian NHS. Results In 2014, the total expenditure for the 103 enrolled HIV-1 patients treated with HAART was €814,543. The mean treatment cost per patient was €7,908. If all patients were treated with the dual therapy (nevirapine and raltegravir), the total expenditure would be €573,298 (-29.6%) with a mean treatment cost per patient of €5,566. Conclusions From the Italian NHS perspective, nevirapine/raltegravir represent a cost-saving option as maintenance antiretroviral therapy in virologically suppressed HIV-1 infected patients.

Downloads

Published

2016-07-18

How to Cite

1.
Ravasio R, Rigo F, Lattuada E, Concia E, Lanzafame M. Economic Evaluation of Nevirapine plus Raltegravir as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1 Infected Patients: Valutazione economica della combinazione nevirapina/raltegravir quale terapia antiretrovirale di mantenimento nei pazienti con infezione da HIV-1 in soppressione virologica. Grhta [Internet]. 2016 Jul. 18 [cited 2022 Oct. 1];3(2):110-4. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/416

Issue

Section

Original Research Articles

Most read articles by the same author(s)

1 2 3 4 > >>